HeartSciences Inc. cash flow to debt ratio of 0.48% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

HeartSciences Inc.'s free cash flow has increased -248.83% from $-6.20M last year to $9.22M, signaling increasing performance

HeartSciences Inc.'s debt to equity ratio is 17.41, which means that the company's assets are unhealthy financed, signaling financial risk.

HeartSciences Inc.'s debt has increased relative to shareholder equity from 14.55 last year to 17.41 today, signaling weakened financials

HeartSciences Inc. has negative EBITDA, making leverage ratio unreliable

HeartSciences Inc.'s interest coverage ratio is -11.17, which means that the company struggles to meet interest obligations, signaling financial risk.

HeartSciences Inc.'s profit margin has decreased (5.05%) in the last year from -201.50K% to -211.67K%, signaling decreasing performance

HeartSciences Inc.'s short-term liabilities of $4.86B exceed its short-term assets of $2.58B, signaling financial risk

HeartSciences Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

HeartSciences Inc.'s return on equity of -358.44%, is lower than 15.00%, indicating bad performance

HeartSciences Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

HeartSciences Inc. has insufficient public price history to evaluate earnings stability.

HeartSciences Inc. has positive free cash flow, indicating the company generates cash after capital expenditures

HeartSciences Inc. has a free cash flow yield of 206.28%, which is above the 2.00% threshold, indicating strong cash generation relative to market value

HeartSciences Inc.'s yearly earnings has decreased 4.30% since last year from $-8.77M to $-9.14M, signaling decreasing performance

HeartSciences Inc.'s yearly revenue has decreased 76.61% since last year from $18.60K to $4.35K, signaling decreasing performance

ROIC -202.10% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

HeartSciences Inc.'s 3-year revenue CAGR of -5.70% is negative, indicating declining revenue over the past 3 years

HeartSciences Inc. had revenue growth in only 1 out of 5 years, indicating inconsistent revenue performance

HeartSciences Inc. has insufficient public price history to evaluate ROE consistency.

HeartSciences Inc. has insufficient data to evaluate this check.

HeartSciences Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

HeartSciences Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

HeartSciences Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

HeartSciences Inc. has insufficient data to evaluate this check.

HeartSciences Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

HeartSciences Inc. has a price-to-book ratio of 28.95x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value

HeartSciences Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue